Minerva Neurosciences, Inc. (NERV)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Minerva Neurosciences, Inc. (NERV) is up 18.2% since the beginning of the year. At $5 per share, NERV is trading 61.9% below its 52-week high of $12. Investors who bought $1,000 worth of NERV shares 5 years ago would now be looking at an investment worth $203.

Minerva Neurosciences, Inc. (NERV) has returned 18.16% so far this year and 170.66% over the past 12 months. Over the last ten years, NERV has returned -26.35% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Jul 1, 2014, NERV's average daily return is +0.17%, while the average monthly return is +3.24%. At this rate, an investment would double in approximately 1.8 years.

Historically, 43% of months were positive and 57% were negative. The best month was Aug 2022 with a return of +320.9%, while the worst month was Oct 2022 at -71.3%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 6 months.

On a daily basis, NERV closed higher 45% of trading days. The best single day was May 26, 2016 with a return of +233.3%, while the worst single day was May 29, 2020 at -72.5%.

Minerva Neurosciences, Inc. has an annualized alpha of 37.14%, beta of 0.87, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since July 02, 2014.

• This stock participated in 118.80% of S&P 500 Index downside but only -2.36% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NERV ranks 86 for risk / return — in the top 86% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Minerva Neurosciences, Inc. (NERV) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Minerva Neurosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Minerva Neurosciences, Inc. was 98.86%, occurring on Apr 9, 2025. The portfolio has not yet recovered.

The current Minerva Neurosciences, Inc. drawdown is 95.96%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Minerva Neurosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Minerva Neurosciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.